| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CAP; MCAP; HUNK1; HUNKI |
| WB Predicted band size | 152 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human BRD4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于BRD4抗体的代表性文献，简要概括其内容：
---
1. **文献名称**: *Selective inhibition of BET bromodomains*
**作者**: Filippakopoulos, P. et al.
**摘要**: 该研究报道了BRD4特异性抑制剂JQ1的开发，通过结构分析揭示BRD4溴结构域与染色质结合的分子机制。文中使用BRD4抗体进行免疫共沉淀(Co-IP)和染色质免疫沉淀(ChIP)，验证了JQ1对BRD4功能的选择性抑制作用。
---
2. **文献名称**: *Brd4 is required for Myc-induced transcriptional amplification*
**作者**: Rahl, P.B. et al.
**摘要**: 研究探讨BRD4在调控MYC介导的转录放大中的功能。利用BRD4特异性抗体进行ChIP-seq和RNA聚合酶II定位分析，发现BRD4通过促进转录延伸复合体的招募，驱动致癌基因的异常表达。
---
3. **文献名称**: *Targeting BRD4 attenuates tumor growth in a murine model of malignant peripheral nerve sheath tumor*
**作者**: Patel, A.J. et al.
**摘要**: 该研究通过BRD4抗体进行Western blot和免疫组化，证实BRD4在恶性外周神经鞘瘤(MPNST)中高表达，并利用BRD4抑制剂联合抗体实验验证其作为治疗靶点的潜力。
---
**备注**：以上文献中使用的BRD4抗体多用于功能研究(如ChIP、WB等)，需结合具体实验目的选择商业化抗体(如Cell Signaling Technology #13440等)。建议通过文献中的抗体验证数据或引用次数较高的抗体品牌进行实验设计。
Bromodomain-containing protein 4 (BRD4), a member of the BET (bromodomain and extraterminal) protein family, plays a critical role in epigenetic regulation by binding to acetylated lysine residues on histones. It facilitates transcriptional activation by recruiting transcriptional regulators, such as Mediator complex and P-TEFb, to chromatin, thereby influencing cell cycle progression, inflammation, and oncogene expression. Dysregulation of BRD4 is implicated in cancers, inflammatory diseases, and viral infections, making it a key therapeutic target.
BRD4 antibodies are essential tools for studying its expression, localization, and molecular interactions. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, chromatin immunoprecipitation (ChIP), and immunofluorescence to investigate BRD4's role in chromatin remodeling, transcriptional elongation, and disease mechanisms. Specific monoclonal or polyclonal antibodies target distinct BRD4 domains (e.g., bromodomains, ET domain) to probe functional interactions or assess inhibitor binding in drug development studies. Validation of BRD4 antibodies is crucial due to potential cross-reactivity with other BET proteins (BRD2. BRD3. BRDT) and splice variants. Recent advances in selective BRD4 inhibitors (e.g., JQ1. OTX015) have further driven demand for reliable antibodies to evaluate target engagement and pharmacodynamic responses in preclinical models and clinical samples.
×
